Weekly Recap: 42% lower melanoma recurrence or death risk and $5.4B peak sales estimate

What happened

Moderna and Merck reported that their Phase 3 melanoma vaccine, intismeran, reduced recurrence or death risk by 42% compared with Keytruda alone. Moderna shares fell about 26% intraday after results leaked. The vaccine could launch in the U.S. in 2027, but filing timing remains unclear.

Confirmed

Global impact / market context

If approved, intismeran could add substantial revenue for Moderna: William Blair estimates peak melanoma sales of $5.4 billion, shared equally with Merck. The 2027 launch target depends on regulatory progress and manufacturing readiness, so delays could postpone sales and extend development costs.

Analyst inference

The reported 42% reduction in recurrence or death risk is a clinical result, not proof of approval or commercial success. The roughly 26% share decline after leaked results shows the news coincided with a sharp move, but the article does not explain its cause.

Analyst inference

What to watch

1. Moderna is scheduled to report quarterly results this week; figures or management comments could clarify spending, cash available, and how the company plans to fund launch preparation. Confirmed
2. Watch for Moderna and Merck to clarify their regulatory discussions and filing schedule; a filing is the formal request for regulators to review the treatment. Proposed
3. Manufacturing capacity and the time from biopsy to dose could affect launch readiness and treatment delivery; delays would likely push back revenue from the targeted U.S. launch. Analyst inference

Evidence

• Original source link unavailable